Characterization of KRAS mutations (mt) in non-small cell lung cancer (NSCLC).

9544Background: KRAS is the most commonly mutated oncogene in NSCLC and the development of direct KRAS inhibitors has renewed interest in this molecular subtype. However, there are several differen...